Drug Trial Radar · NCT05176626
Long-term Effectiveness of the Antiobesity Medication Phentermine
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
870
Actual
Start
Jun 30, 2022
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Wake Forest University Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Johns Hopkins University; Kaiser Permanente; HealthPartners Institute; The University of Texas Health Science Center, Houston; Biomedical Research Institute of New Mexico; WW International Inc; KVK-Tech, Inc.; National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jan 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.
Conditions
- Obesity
- Obesity; Drug
- Lifestyle, Healthy
Interventions
Online Lifestyle Behavioral TherapyBehavioral
Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
Phentermine Hydrochloride 8 MGDrug
At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in body weight (%)Time frame: Baseline to month 24
- Change in Systolic Blood Pressure (mmHg)Time frame: Baseline to month 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente Southern California
Los Angeles, California
HealthPartners Institute
Saint Louis Park, Minnesota
Atrium Health Wake Forest Baptist Weight Management Center
Winston-Salem, North Carolina
UT Center for Obesity Medicine and Metabolic Performance
Bellaire, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.